Supplementary Table S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial

2026 Open access

Read full text
Authors: Mafalda Oliveira, Eva Ciruelos, Guillermo Javierre Villacampa, Serafin M. Morales, Javier Salvador Bofill, Vanesa Quiroga, Joaquín Gavilá, Alexandra Cortegoso, Estela Vega, Fernando Henao, Sònia Servitja, Pablo Tolosa
+8 more Samyukta Chillara, Milana A. Bergamino, Fernando Salvador, Mariana Paes Dias, Juan Manuel Ferrero-Cafiero, Xavier González, Tomás Pascual, Cristina Saura
DOI: 10.1158/1078-0432.31248950
Cited by: 0

Abstract

Supplementary Table S4 | Drug-related dose interruptions, dose reductions, and treatment discontinuations (N = 17)

Fields of Study & Subjects

HER2/EGFR in Cancer Research PI3K/AKT/mTOR signaling in cancer Advanced Breast Cancer Therapies

Publication details

Publication date
4 February 2026
Language
EN